AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04093765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antimalarials
Description: A safe, recommended treatment of P. falciparum malaria will be administered to URDT positive individuals based on participant's characteristics:~* The standard regimen for participants without known antimalarial allergy, not pregnant and not breastfeeding, will be a 3-day supervised weight-adjusted DP course and a single low dose PMQ. The single low dose PMQ will be administered on the first day.~* Pregnant women and in their 2nd or 3rd trimester, and breastfeeding mothers, will receive a DP course but no PMQ.~* Pregnant women in their first trimester will receive an oral course of quinine+clindamycin (7 days).~* Individuals with known drug allergy to piperaquine will be treated with AL (+/- sld PMQ as per their pregnancy/breastfeeding status)~* Specific/complex cases will be assessed by a medic and referred to a health facility for treatment if necessary.
Study NCT02885870 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combination of multiparametric MRI and electrophysiology
Description: MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
Study NCT01162174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oligonol
Study NCT00821288 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facing Forward
Description: Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
Study NCT02109913 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Everolimus plus Exemestane
Description: Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
Study NCT00928642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Intravenous
Description: Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cis will be administered at a dose of 80 mg/m\^2 as intravenous infusion on Day 1.
Study NCT03909724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
Study NCT03909724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS 102
Description: After study inclusion, patients will be randomized (1:1) via a centralized randomization system to receive either oral sunitinib (700 mg once every 2 weeks) or TAS-102 (35 mg per square meter, twice daily, 5 days a week, with 2 days of rest, for 2 weeks, followed by a 14-day rest period). Patients will receive treatment until disease progression or discontinuation due to unacceptable toxic effects, withdrawal of consent, or other reason.
Study NCT01732861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-292
Description: CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
Study NCT01732861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
Study NCT03034278 — intervention group
Intervention type: OTHER
Intervention: Not applicable - no intervention
Description: Not applicable - no intervention, observational survey study.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (Gem) will be administered at a dose of 1250 mg/m\^2 as intravenous infusion on Days 1 and 8.
Study NCT03004833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Infusion of Nivolumab
Study NCT03004833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: Infusion of Adriamycin
Study NCT03004833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Infusion of Vinblastine
Study NCT03004833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: Infusion of Dacarbazine
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine (Vin) will be administered at a dose of 25 mg/m\^2 as intravenous infusion on Days 1 and 8.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Participants will receive IV infusion of oleclumab as stated in arm description.
Study NCT00842712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilengitide
Description: Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.
Study NCT01162174 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oligonol
Study NCT01548729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined pancreatic islet and lung transplantation
Description: Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
Study NCT02941861 — intervention group
Intervention type: OTHER
Intervention: Recurrence Rate of HCC after surgery
Description: Recurrence Rate of HCC after surgery
Study NCT02941861 — intervention group
Intervention type: OTHER
Intervention: Recurrence Rate of CCA after surgery
Description: Recurrence Rate of CCA after surgery
Study NCT04034069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive IV infusion of gemcitabine as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Participants will receive IV infusion of nab-paclitaxel as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive IV infusion of oxaliplatin as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive IV infusion of folinic acid as stated in arm description.
Study NCT03611556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Participants will receive IV infusion of 5-FU as stated in arm description.
Study NCT02721407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retroviral vector-transduced autologous T cells to express CD22-specific CARs
Study NCT00591136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indibulin
Description: Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
Study NCT00317395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Otamixaban (XRP0673)
Description: intravenous administration
Study NCT00031746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: soy protein isolate
Description: 25 mg daily
Study NCT00031746 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: casein proteins
Description: 25 mg daily
Study NCT04346108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (IGIV)
Description: Participants will receive IGIV infusion.
Study NCT04346108 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Subcutaneous, 20% Solution (IGSC, 20%)
Description: Participants will receive IGSC, 20% SC infusion.
Study NCT04034069 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
Study NCT04034069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theta burst stimulation (TBS)
Description: Theta burst stimulation (TBS) is a potent form of repetitive transcranial magnetic stimulation (rTMS). Standard 600-pulse intermittent theta burst stimulation (iTBS) can enhance the corticomotor excitability, whereas standard 600-pulse continuous theta burst stimulation (cTBS) can suppress the corticomotor excitability. Sham stimulation uses an extreme low stimulation intensity which will not influence with corticomotor excitability. In the present study, real stimulation will be delivered in an intensity of 70% individual resting motor threshold while sham stimulation will be delivered in an intensity of 20% individual resting motor threshold.
Study NCT04034069 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Robot-assisted training
Description: Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
Study NCT03800589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification with implantation of the Ex-Press
Description: The conjunctiva is dissected with the base in the limbus. A square scleral flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Mini seton was implanted at 12 o'clock according to the standard technique.
Study NCT04034069 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Robot-assisted training
Description: Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
Study NCT04034069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Description: Fourier M2 upper limb rehabilitation robot (Fourier Intelligence Co. Ltd., Shanghai, China), will be used for upper limb proximal joints training. Fourier M2 upper limb rehab robot is an end-effector robot-assisted device. The device targets (1) flexion and extension of shoulder joint, (2) flexion and extension of elbow, (3) internal and external rotation of shoulder joint, and (4) abduction and adduction of shoulder joint, supported by tailored interactive TV games in the device. HandyRehab hand robot (Zunosaki Company Ltd., Hong Kong SAR) will be used for upper limb distal joints training. It is an exoskeleton over the hand which provides power-driven extension and grasping force to the fingers and thumb in order to assist the patient to open and close the paretic hand by means of surface electromyography-triggered from the signals through the forearm extensors and flexors.
Study NCT04065295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1356225
Description: Oral Dose
Study NCT04065295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral dose
Study NCT02582151 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine
Description: Percutaneous patch electrodes are used to deliver low level electrical currents.
Study NCT02582151 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine
Description: Percutaneous patch electrodes are used to deliver low level electrical currents.
Study NCT02316379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 129 Xenon
Description: During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
Study NCT02316379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT03008928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcooquizz
Study NCT04957810 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WeChat Mini Program
Description: Through the WeChat applet, it provides services such as visit content configuration, self-image configuration, self-image measurement configuration, and visit reminders.
Study NCT05022706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based accompaniment and home visits
Description: Trained health promoters will accompany adolescents to their first appointments; facilitate enrollment in public health insurance and completion of other administrative requisites (e.g. obtaining a foreign identification card for migrants; transferring to a different health facility); help troubleshoot new logistical and/or social challenges; and will foster communication between the adult care providers and the patient.~Health promoters will visit the participant's home or another mutually-agreed upon location at least monthly, to review ART adherence, identify barriers to care and adherence, remind patients of upcoming medical encounters, screen and follow-up for clinical and social problems, and offer social support.
Study NCT00317395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: intravenous administration
Study NCT04520256 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Interactive Video Feedback
Description: Video-recorded messages are used to provide periodic feedback on progress with weight loss, dietary change, and physical activity. Additional videos provide dietary skills training.
Study NCT03800589 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: deep sclerectomy, phacoemulsification, ExPress implantation
Description: The conjunctiva is dissected with the base in the limbus. Superficial flap is dissected with the based in the limbus. Phacoemulsification is performed through a corneal incision 2.75 mm from the temple using the phaco-chop technique. Deep scleral is dissected just below the trabeculo-Descemet membrane. The seton is implanted in the anterior chamber at the height of Schlemm's Canal.
Study NCT00668018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levitra (Vardenafil, BAY38-9456)
Description: Vardenafil 10mg orally on demand prior to intercourse
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% dextrose in water
Description: 60 ml IV infusion over 30 minutes
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 40 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 80 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 160 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 320 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days
Study NCT00612014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TZP-101
Description: 600 micrograms/kg iv 2ml/minute for 30 minutes~1 infusion/day for 4 consecutive days
Study NCT02917213 — intervention group
Intervention type: OTHER
Intervention: Doppler echocardiogram exam
Description: A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
Study NCT02917213 — intervention group
Intervention type: OTHER
Intervention: Carotid duplex ultrasound exam
Description: A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
Study NCT05022706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy
Description: Among adolescents who have already initiated combination antiretroviral therapy (cART), directly observed therapy (DOT) will be provided to the subset of adolescents identified as being at high risk of non-adherence, defined by meeting at least one of the following criteria: 1) identified by the pediatric health provider as having unstable adherence; or 2) having a detectable viral load at one of their two previous measurements. In adolescents newly initiating cART, there will not be an adherence precedent. This group will choose whether they wish to receive DOT. As part of this research, trained community health workers (CHWs) will deliver DOT in participant's homes or in a mutually agreed upon location. CHWs will observe ingestion of cART daily, ensure it is taken as prescribed and record each dose as DOT, self-administered, not taken or not prescribed.